tommyboy14
Well-known member
Hi Team,
Although the Proact Xa trial failed, it looks like there are now new Anticoagulants on the horizon which cause less bleeding. They are only in clinical trials now, so we will not know for a couple of years how they even compare to Apixaban. However, if this comes through, I wouldnt be surprised if On-X or somebody else try another clinical trial with this new generation of Anticoagulants.
www.ncbi.nlm.nih.gov
Perhaps this will a substitute for Warfarin one day, but we will probably not know for at least another 10 years or so...
Happy new year everybody
Tommyboy
Although the Proact Xa trial failed, it looks like there are now new Anticoagulants on the horizon which cause less bleeding. They are only in clinical trials now, so we will not know for a couple of years how they even compare to Apixaban. However, if this comes through, I wouldnt be surprised if On-X or somebody else try another clinical trial with this new generation of Anticoagulants.

Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders
Bleeding is the dominant adverse event of anticoagulation and often discourages many patients and physicians from starting treatment with anticoagulant drugs. The fact that factor (F)XI deficiency is associated with a mild bleeding phenotype and that ...

Perhaps this will a substitute for Warfarin one day, but we will probably not know for at least another 10 years or so...
Happy new year everybody
Tommyboy